Phase 1 Small Lymphocytic Lymphoma Clinical Trials
24 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 24 trials
Recruiting
Phase 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+6 more
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Phase 1Phase 2
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Mantle Cell LymphomaSmall Lymphocytic LymphomaB-cell Non Hodgkin Lymphoma+2 more
AstraZeneca408 enrolled64 locationsNCT06564038
Recruiting
Phase 1
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Mantle Cell Lymphoma (MCL)+4 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.85 enrolled9 locationsNCT06980116
Recruiting
Phase 1
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Recurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia+5 more
Mayo Clinic25 enrolled1 locationNCT04892277
Recruiting
Phase 1
Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL
Relapsed or Refractory CD19+ B-cell LymphomaRelapsed or Refractory Chronic Lymphocytic LeukemiaRelapsed or Refractory Small Lymphocytic Lymphoma
University Health Network, Toronto19 enrolled1 locationNCT05963217
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines645 enrolled130 locationsNCT05006716
Recruiting
Phase 1Phase 2
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
Acute Lymphoblastic LeukemiaSmall Lymphocytic LymphomaLymphoblastic Lymphoma+4 more
National Cancer Institute (NCI)132 enrolled1 locationNCT06364423
Recruiting
Phase 1
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Acute Myeloid LeukemiaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+10 more
Newave Pharmaceutical Inc100 enrolled8 locationsNCT04771572
Recruiting
Phase 1
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Diffuse Large B-Cell Lymphoma+16 more
City of Hope Medical Center37 enrolled1 locationNCT06859008
Recruiting
Phase 1Phase 2
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Phase 1Phase 2
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaChronic Lymphocytic Leukemia+10 more
Vironexis Biotherapeutics Inc.32 enrolled9 locationsNCT06533579
Recruiting
Phase 1
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+5 more
Nurix Therapeutics, Inc.248 enrolled16 locationsNCT04830137
Recruiting
Phase 1
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Recurrent Chronic Lymphocytic LeukemiaRecurrent Follicular LymphomaRecurrent Small Lymphocytic Lymphoma+12 more
Mayo Clinic27 enrolled1 locationNCT06191887
Recruiting
Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Chronic Lymphocytic LeukemiaNon-Hodgkin LymphomaSmall Lymphocytic Lymphoma+1 more
Imugene Limited135 enrolled23 locationsNCT03666000
Recruiting
Phase 1
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Diffuse Large B Cell LymphomaNon-Hodgkin LymphomaMantle Cell Lymphoma+7 more
C. Babis Andreadis36 enrolled1 locationNCT04545762
Recruiting
Phase 1Phase 2
Mosunetuzumab for CLL MRD Clearance
Chronic Lymphocytic LeukemiaLymphomaLeukemia+1 more
Inhye Ahn40 enrolled2 locationsNCT07052695
Recruiting
Phase 1
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Chronic Lymphocytic LeukemiaNon-Hodgkin LymphomaMantle Cell Lymphoma+5 more
Carna Biosciences, Inc.120 enrolled13 locationsNCT05602363
Recruiting
Phase 1
A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas
CLL/SLLCLL (Chronic Lymphocytic Leukemia)SLL (Small Lymphocytic Lymphoma)
Lomond Therapeutics Holdings, Inc.66 enrolled4 locationsNCT06708897
Recruiting
Phase 1Phase 2
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+5 more
CRISPR Therapeutics AG120 enrolled7 locationsNCT05643742
Recruiting
Phase 1
Q702 for the Treatment of Patients With Hematologic Malignancies
Hematopoietic and Lymphatic System NeoplasmHistiocytic SarcomaMalignant Histiocytosis+34 more
Mayo Clinic46 enrolled2 locationsNCT06712810